-
The wave of Industry 4.0 revolution is surging, sweeping the pharmaceutical equipment industry
Time of Update: 2022-10-20
com) The pharmaceutical equipment industry is an important part of China's manufacturing industry, but the traditional growth model has been weak, coupled with the rising labor costs year by year, from "manufacturing" to "intelligent manufacturing" innovation transformation has become the expectation of the pharmaceutical machinery industry.
-
In 2022, the overall investment and financing trend in the medical and health field will slow down
Time of Update: 2022-10-20
In recent years, the research and development of domestic innovative drugs has been hot, but the targets are piled up, the track is crowded, and the involution is serious, which has caused the development of the innovative drug industry to fall into a bottleneck period, coupled with the impact of medical insurance control fees, the epidemic and other factors, the investment and financing in the domestic medical and health field are "deserted" compared with last year.
-
National Medical Insurance Administration: The expert review of the adjustment of the medical insurance drug catalogue has been completed
Time of Update: 2022-10-19
Among them, if the evaluation result is "new to be negotiated" and "new to be added", it means that the drug has been included in the negotiation/bidding scope of the 2022 national medical insurance drug catalogue and has obtained the negotiation/bidding qualification, which does not mean that the drug has been included in the 2022 national medical insurance drug catalogue.
-
German Merck increases M&A investment! Pfizer, AstraZeneca, Novo Nordisk and other MNCs are actively "picking the bottom"! Innovative biotechnology opportunities and risks?
Time of Update: 2022-10-19
Merck said that the group plans to further increase global targeted investment and expand its leadership position in the field of bioscience and technology on the basis of its own research and development on the basis of its own research and development in the three core businesses of life science, health care and semiconductors from 2023.
-
Recently, a number of innovative drugs from domestic and foreign pharmaceutical companies have been approved for clinical trials
Time of Update: 2022-10-19
Pfizer: ARV-471 (PF-07850327) tablets Recently, according to the website of the Center for Drug Evaluation (CDE) of the China National Food and Drug Administration, Pfizer's ARV-471 (PF-07850327) tablet clinical trial application passed the "implied permission".
-
The second batch of varieties of Chinese medicinal materials produced in Shandong Province is freshly cut and processed
Time of Update: 2022-10-19
According to the Reply of the Comprehensive Department of the State Food and Drug Administration on Issues Related to the Procurement of Chinese Materia Medica Materials by Manufacturers of Tradition
-
Within a year, 3 deputy general managers of the pharmaceutical company left! In 2021, the pre-tax remuneration will exceed 4 million yuan
Time of Update: 2022-10-19
Among them, Hengrui Pharmaceutical has resigned three deputy general managers since the beginning of the year, namely Tao Weikang, Zou Jianjun and Zhang Yuehong.
Among them, Hengrui Pharmaceutical has resigned three deputy general managers since the beginning of the year, namely Tao Weikang, Zou Jianjun and Zhang Yuehong.
-
Phase 1 clinical results of Sibiman's second-generation CAR-T product were announced, with an objective response rate of 96.4%
Time of Update: 2022-10-19
▲ Image source: ReferenceC-CAR088 is a novel second-generation CAR-T cell targeting BCMA with 4-1BB as the co-stimulatory factor, and its preliminary clinical trial results show good efficacy and safety.
-
The internationalization of traditional Chinese medicine has been accelerating, and another Chinese medicine product has been exported overseas
Time of Update: 2022-10-19
js?cdnversion='+~(-new Date()/36e5)]; In recent years, China has carried out pragmatic cooperation in the field of traditional Chinese medicine with countries that jointly built the "Belt and Road", and has achieved positive results in trade development, standard setting, medical care and education.
-
Traditional Chinese medicine cholining tablets were successfully exported to Canada and entered the international mainstream drug market
Time of Update: 2022-10-19
(End) The reporter learned on the 15th that the traditional Chinese medicine cholening tablets were officially shipped and went to sea to Toronto, Canada.
(End) The reporter learned on the 15th that the traditional Chinese medicine cholening tablets were officially shipped and went to sea to Toronto, Canada.
-
Notice on the public solicitation of opinions on the "Technical Guidelines for the Study of Microbial Limits of Non-sterile Chemicals and Raw Materials (Draft for Comments)"
Time of Update: 2022-10-19
Notice on the public solicitation of opinions on the "Technical Guidelines for the Study of Microbial Limits of Non-sterile Chemicals and Raw Materials (Draft for Comments)" Release date: 20221010 In
-
The demand for winter grass is limited, and it is difficult for the price to continue to rise!
Time of Update: 2022-10-19
Third, the demand is relatively declining and the output is stable Dongling grass is a small and medium-sized variety, formerly mainly supplied to the market with wild sources, widely distributed in China, but there are not many areas with harvesting habits, the traditional production areas are in Jiyuan City, Henan Province, Xia County, Wenxi County and other places around Yuncheng City, Shanxi.
-
High-end preparations: under the normalization of centralized procurement, the new direction of differentiation and breakthrough of pharmaceutical companies
Time of Update: 2022-10-19
"Special Report on Microsphere Liposomes: The General Trend of Preparation Upgrade, Ten Billion Blue Ocean "Micro" Visible", GF Hang Seng, 2018-10-25 。 1 preface In the context of the normalization of drug procurement in China, the pharmaceutical industry has developed to the second half of high-end upgrading and differentiated breakthrough, and the investment and risk of innovative drug development are high, and the homogenization competition of some targets is serious.
-
In 2021, the total sales of seven categories of pharmaceutical products in China will exceed 2.6 trillion yuan
Time of Update: 2022-10-19
In addition, the digital transformation of the pharmaceutical circulation industry has accelerated, the number of pharmaceutical e-commerce orders has increased significantly, and China's drug supply guarantee capacity has been greatly improved.
-
In October, a number of multinational pharmaceutical companies launched large-scale acquisitions to increase the layout of rare diseases
Time of Update: 2022-10-19
In October, Pfizer's acquisitions in the field of rare diseases also continued, and it launched two acquisitions on October 3 and 5 local time, including: Alexion Pharmaceuticals, a subsidiary of its rare disease business, announced the acquisition of clinical-stage genomics company LogicBio Therapeutics for $68 million, and acquired Biohaven for $11.
-
Announcement of the State Food and Drug Administration on amending the instructions of pentoxifylline injection
Time of Update: 2022-10-19
The MAHs of the above-mentioned drugs shall, in accordance with the Measures for the Administration of Drug Registration and other relevant provisions, report to the Drug Evaluation Center of the State Medical Products Administration or the provincial drug regulatory department for the record before January 14, 2023 in accordance with the requirements for the revision of the instructions for pentoxifylline injection (see annex).
-
Innovative medical devices will not be collected for the time being; CR and Fosun announced cooperation; 33 medical consumables face network withdrawal; The in vitro diagnostic sector is pulling up strongly...
Time of Update: 2022-10-19
The National Medical Insurance Administration also further clarified: for innovative products such as 3D printed orthopedic consumables, considering the characteristics of technical characteristics, production costs, usage, clinical efficacy and other characteristics, adopt the "one product and one policy" approach, determine appropriate procurement rules, improve the market-oriented price formation mechanism, promote the high-quality development of the medical device industry, and provide more innovative products for the people at reasonable prices.
-
From November 1, the electronic registration certificate for drugs will be issued, which has the same legal effect as the paper registration certificate
Time of Update: 2022-10-19
On October 9, the State Food and Drug Administration issued an announcement that it will issue electronic registration certificates for drugs from November 1, 2022, including certificates for drug clinical trials, drug marketing authorization, drug re-registration, drug supplement application, protection of traditional Chinese medicine varieties, imported medicinal materials, chemical APIs, etc.
-
Open solicitation of guidelines for the production and processing of Chinese herbal medicines in Shanxi Province
Time of Update: 2022-10-19
In accordance with the requirements of the General Department of the State Food and Drug Administration, the "Reply Letter on Issues Related to the Procurement of Chinese Materia Medica Materials fro
-
Notice on publicly soliciting opinions on the Catalogue of Reference Preparations for Chemical Generic Drugs (Batch 63) (Draft for Comments).
Time of Update: 2022-10-19
Center for Drug Evaluation of the State Medical Products Administration October 9, 2022 Related attachments serial number Attachment name 1 The Catalogue of Reference Preparations for Chemical Generic Drugs (Batch 63) (Draft for Comments) is .
